Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post hoc analysis of the TAXIT trial

Gut

Volumn 67, Issue 5, 2018, Pages 818-826

  Van Stappen, Thomas ^a   Vande Casteele, Niels ^a   Van Assche, Gert ^b   Ferrante, Marc ^b   Vermeire, Séverine ^b   Gils, Ann ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CLINICAL DECISION MAKING; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB

Indexed keywords

INFLIXIMAB; ANTIBODY; GASTROINTESTINAL AGENT;

ADULT; ANTIBODY DETECTION; ARTICLE; ASSAY; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERANCE; DRUG TOLERANT ASSAY; FEMALE; HUMAN; IMMUNODETECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCREENING TEST; TROUGH CONCENTRATION; ULCERATIVE COLITIS; BLOOD; DRUG MONITORING; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED;

EID: 85046490601     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-313071     Document Type: Article

References (40)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
4. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
5. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
6. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis 2016;10:619-25.
7. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014;147:1296-307.
8. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.
9. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27.
10. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013;19:2568-76.
11. D'Haens GR, Vermeire S, Lambrecht G, et al. 692 Drug-level based dosing versus symptom-based dose adaptation in patients with Crohn's disease: a prospective, randomized multicenter study (TAILORIX). Gastroenterology 2016;150:S143.
12. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
13. van Schie KA, Hart MH, de Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:311-14.
14. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.
15. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-64.
16. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7.
17. Van Stappen T, Brouwers E, Vermeire S, et al. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal 2017;9:243-7.
18. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88.
19. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012;18:1628-33.
20. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765-71.
21. Van Stappen T, Billiet T, Vande Casteele N, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:2172-7.
22. Bourdage JS, Cook CA, Farrington DL, et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods 2007;327:10-17.
23. Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid test for infliximab drug concentration allows immediate dose adaptation. Clin Transl Gastroenterol 2016;7: e206.
24. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301.
25. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
26. Loomes DE, Teshima C, Jacobs P, et al. Health care resource use and costs for Crohn's disease before and after infliximab therapy. Can J Gastroenterol 2011;25:497-502.
27. Arias MT, Vande Casteele N, Vermeire S, et al. A Panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:531-8.
28. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013;7:736-43.
29. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:447-59.
30. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:378.
31. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
32. van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;362:82-8.
33. van Schouwenburg PA, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
34. Bloem K, van Leeuwen A, Verbeek G, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015;418:29-38.
35. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17.
36. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-7.
37. Strik AS, van den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1128-34.
38. Pavlov IY, Carper J, Lázár-Molnár E, et al. Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clin Chim Acta 2016;453:147-53.
39. Weisshof R, Ungar B, Blatt A, et al. Anti-infliximab antibodies with neutralizing capacity in patients with inflammatory bowel disease: distinct clinical implications revealed by a novel assay. Inflamm Bowel Dis 2016;22:1655-61.
40. Zoghbi J, Xu Y, Grabert R, et al. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods 2015;426:62-9.